Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
Go back to Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 9.98 -0.01 (0.1%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.99 | 52 Week High | $9.23 | |||
| Open | $9.75 | 52 Week Low | $1.16 | |||
| Day High | $10.05 | P/E | N/A | |||
| Day Low | $9.53 | EPS | $-0.30 | |||
| Volume | 3,883,076 | |||||
| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 9.98 -0.01 (0.1%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.99 | 52 Week High | $9.23 | |||
| Open | $9.75 | 52 Week Low | $1.16 | |||
| Day High | $10.05 | P/E | N/A | |||
| Day Low | $9.53 | EPS | $-0.30 | |||
| Volume | 3,883,076 | |||||
